MedTrace Logo

Canadian Medical Assessment of JINARC™ Outcomes Registry

NCT02925221 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 530

Last updated 2026-01-07

No results posted yet for this study

Summary

This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a set of Patient Reported Outcome (PRO) Questionnaires. The study is also describing the time to renal replacement therapy (RRT), such as dialysis and transplantation, and the long-term mortality rate and causes (i.e. renal and hepatic), in ADPKD patients treated with JINARC™ (tolvaptan)

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sponsors & Collaborators

  • Otsuka Canada Pharmaceutical Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-26
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02925221 on ClinicalTrials.gov